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Abstract
Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that markedly elevates plasma
low-density lipoprotein (LDL) cholesterol and causes premature coronary heart disease. There are at least 20 million
people with FH worldwide, but the majority remains undetected and current treatment is often suboptimal.
To address this major gap in coronary prevention we present, from an international perspective, consensus-based
guidance on the care of FH. The guidance was generated from seminars and workshops held at an international
symposium. The recommendations focus on the detection, diagnosis, assessment and management of FH in adults
and children, and set guidelines for clinical purposes. They also refer to best practice for cascade screening and risk
notifying and testing families for FH, including use of genetic testing. Guidance on treatment is based on risk stratification,
management of non-cholesterol risk factors and safe and effective use of LDL lowering therapies. Recommendations are
given on lipoprotein apheresis. The use of emerging therapies for FH is also foreshadowed.
This international guidance acknowledges evidence gaps, but aims to make the best use of contemporary practice and
technology to achieve the best outcomes for the care of FH. It should accordingly be employed to inform clinical
judgment and be adjusted for country-specific and local healthcare needs and resources.
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Levels of evidence and grades of
recommendation
Levels of evidence
1¼ systematic review/meta-analysis/at least one rando-
mized control trial/good quality diagnostic tests.
2¼ good quality clinical or observational studies.
3¼ expert opinion or clinical experience/argument
from first principles.
(The evidence for therapeutic interventions was
considered principally in respect of effects on plasma
low-density lipoprotein (LDL)-cholesterol concentra-
tions, but where available was also based on data on
subclinical atherosclerosis or cardiovascular outcomes.)
Grades of recommendation
A¼ can be trusted to guide practice.
B¼ can be trusted to guide practice in most situations.
C¼ can be used to guide practice, but care should be
taken in application.
Summary of recommendations
1. Detection of index cases: screening and
phenotypic diagnosis
1.1 Targeted, opportunistic and universal screening
strategies should be employed to detect index
cases (2B).
1.2 Index cases should be sought by targeted
screening of adults with premature cardiovascular dis-
ease (CVD), primarily coronary heart disease (CHD)
and a personal and/or family history of hypercholester-
olaemia. (1A)
1.3 Opportunistic screening of adults and children in pri-
mary care, based on age- and gender-specific plasmaLDL-
cholesterol levels, should be routinely adopted. (2B)
1.4 Universal screening based on age- and gender-
specific plasma LDL-cholesterol levels should be
considered prior to age 20 years and ideally before
puberty. (2C)
1.5 In adults, country-specific clinical tools, such as the
Dutch Lipid Clinic Network, Simon Broome, MED-
PED or Japanese FH criteria, may be used to make a
phenotypic diagnosis. (1A)
1.6 The effect of acute illness and concurrent use of
statins in lowering plasma LDL-cholesterol must be
considered: testing for familial hypercholesterolaemia
(FH) should not be carried out during acute illness;
LDL-cholesterol level should be appropriately
adjusted in people on statins, particularly if a reli-
able pre-treatment value is not available. (2A)
1.7 All patients with suspected FH should be referred to
a clinic specializing in lipidology and/or metabolic dis-
orders for further assessment, if such a service is avail-
able. (3A)
2. Diagnosis and assessment of adults
2.1 Secondary causes of hypercholesterolaemia should
first be excluded. (1A)
2.2 The most reliable diagnosis of FH can be made
using both phenotypic (see 1.5 above and 4.8 below)
criteria and genetic testing, but when genetic testing
is not available the diagnosis can be made phenotypic-
ally. (1A)
2.3 DNA testing increases the accuracy of detecting FH
and, if resources permit, should be considered to confirm
the diagnosis, especially if cascade screening is planned;
a fully accredited laboratory should be used. (1A)
2.4 Although FH is a life-time coronary risk equivalent,
patients should be assessed for additional major cardio-
vascular risk factors, including lipoprotein(a) (Lp(a)),
the level of hypercholesterolaemia at diagnosis and the
prematurity of the family (especially first-degree rela-
tives) or personal history of CVD. Framingham or
other cardiovascular risk equations should not be
used. (2A)
2.5 The presence of additional cardiovascular risk
factors should guide the intensity of medical manage-
ment. (2A)
2.6 Cardiovascular imaging (e.g. cardiac computed
tomography (CT) and carotid ultrasonography) may
be useful for assessing asymptomatic patients, but its
value is not fully established. (2C)
3. Diagnosis and assessment of children
and adolescents
3.1 Secondary causes of hypercholesterolaemia should
first be excluded. (1A)
3.2 With the exceptions noted in 3.3, children should be
genetically tested for FH only after a pathogenic
Conversion factor: mg/dl cholesterol¼mmol/l 38.7; mg/dl
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variant (mutation) has been identified in a parent or
first degree relative. (1A)
3.3 Children may initially be genetically tested for FH
when parents or first degree relatives are unknown or
deceased, or as an accepted screening practice in certain
countries, such as the Netherlands. (3B)
3.4 Age-, gender- and country-specific plasma LDL-
cholesterol concentration thresholds should be used to
make the phenotypic diagnosis; because of biological
variation, two fasting LDL-cholesterol values are rec-
ommended. (1B)
3.5 A plasma LDL-cholesterol of 5.0mmol/l or above
indicates high probability of FH in the absence of a
positive parental history of hypercholesterolaemia or
premature CHD; an LDL-cholesterol of 4.0mmol/l or
above indicates high probability of FH in the presence
of a positive parental history of hypercholesterolaemia
or premature CHD. (1B)
3.6 Patients should be risk stratified according to age,
presence of other cardiovascular risk factors, family his-
tory of early onset CVD (especially in first-degree rela-
tives) and the level of LDL-cholesterol at diagnosis. (2A)
3.7 The presence of additional cardiovascular risk fac-
tors, and hence risk stratification, should guide the
intensity of medical management. (3A)
3.8 Carotid ultrasonography may be employed to
assess risk, but its value is not fully established; it
should only be carried out in centres with specific
expertise. (2C)
3.9 Cardiac CT should not be used routinely to assess
patients with heterozygous FH. (3A)
4. Cascade screening: testing and risk notification
of families
4.1 Notification of relatives at risk of FH should gen-
erally not be carried out without the consent of the
index case. (3A)
4.2 Relatives should only be directly notified of their
risk without consent of the index case if there is specific
legislative provision for breach of confidentiality in the
relevant jurisdiction. (3C)
4.3 A proactive approach that respects the principles of
privacy, justice and autonomy is required. (3A)
4.4 Pre-testing counselling should be offered to at risk
family members of an index case prior to any form of
testing. (1A)
4.5 Systematic cascade screening should ideally be co-
ordinated by a dedicated centre and should not be car-
ried out in primary care without central co-ordination,
particularly if employing DNA testing. (1B)
4.6 Cascade screening of families should be carried out
using both a phenotypic and genotypic strategy, but if
DNA testing is not available a phenotypic strategy
alone should be used. (1A)
4.7 Cascade screening should initially be carried out as
a priority in first-degree relatives and then extended to
second- and third-degree relatives. (1A)
4.8 In the absence of genetic testing, the diagnosis of
FH should be made in close relatives using age-,
gender- and country-specific plasma LDL-cholesterol
levels. Diagnostic clinical tools for index cases, such
as the Dutch Lipid Clinic Network and Simon
Broome criteria, should not be employed to make the
diagnosis of FH in relatives. (1A)
4.9 DNA testing makes cascade screening more cost-
effective and should be employed to screen family mem-
bers after the mutation is identified in the index case. (1A)
4.10 Children with xanthomata or other physical find-
ings of homozygous FH, or at risk of homozygous FH
should be screened as early as possible and definitely by
two years of age. (2A)
4.11 Children with suspected heterozygous FH should be
screened between the ages of five and 10 years; age at
screening should be similar in boys and girls. (2B)
5. Genetic testing
5.1 Genetic testing for FH should ideally be offered to
all ‘index cases’ who have a phenotypic diagnosis of
FH. (3A)
5.2 When the phenotypic diagnosis of FH is unlikely
(e.g. by Dutch Lipid Clinic Network Criteria),
genetic testing of the ‘index case’ need not be carried
out. (1C)
5.3 Genetic testing for FH must be carried out in an
accredited laboratory using standardized methods that
target specific mutations and/or by exon-by-exon
sequencing. (1A)
5.4 If genetic testing detects a variant, its significance as
a pathogenic mutation, a previously reported variant of
uncertain significance, a novel variant of uncertain sig-
nificance or a benign (normal) variant needs to be
assessed and recorded. (1A)
5.5 If genetic testing does not detect a variant, FH due
to undetected mutations or mutations in untested genes
cannot be excluded, particularly if the clinical pheno-
type is strongly suggestive of FH. (1A)
6. Management of adults
6.1 All adult patients with FH must receive advice on
lifestyle modifications and advice to correct all non-
cholesterol risk factors should be provided according
to expert recommendations. (2A)
6.2 Therapy should ideally aim for at least a 50%
reduction in plasma LDL-cholesterol, followed by an
LDL-cholesterol <2.5mmol/l (absence of CHD or
other major risk factors) and <1.8mmol/l (presence
of CHD or other major risk factors). (2C)
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6.3 Achieving these targets will require a fat-modified,
heart-healthy diet and statin therapy with or without
ezetimibe. (1A)
6.4 Drug combinations including bile acid sequestrants,
niacin, probucol or fibrates, may be required with more
intensive strategies to further reduce LDL-cholesterol.
(1B)
6.5 Plasma levels of hepatic aminotransferases, creatine
kinase, glucose and creatinine should be measured
before starting drug therapy. All patients on statins
should have hepatic aminotransferases monitored; cre-
atine kinase should be measured when musculoskeletal
symptoms are reported; glucose should be monitored
when there are risk factors for diabetes. (2A)
6.6 All women of child-bearing age should receive pre-
pregnancy counselling, with appropriate advice on
contraception, before starting a statin and this should
be reinforced at annual review. (2A)
6.7 Statins and other systemically absorbed lipid regu-
lating drugs should be discontinued three months
before planned conception, as well as during pregnancy
and breast feeding. (2A)
6.8 Although carotid ultrasonography has been used in
clinical trials, its role in monitoring therapy as part of the
clinical care for FHhas not been established and it should
therefore not be used at present for this purpose. (3C)
6.9 Lomitapide and mipomersen should be considered
as adjunctive treatments to diet and cholesterol lower-
ing drugs in adults with homozygous FH to further
reduce plasma LDL-cholesterol, particularly if lipopro-
tein apheresis is not available. (1C)
6.10 Well controlled and low complexity patients
should be followed up in primary care, whereas
higher complexity patients will need regular review by
a specialist, with the option of shared care. Review
intervals should vary according to clinical context.
Opportunities should be created for integrating the pri-
mary and specialist care of FH. (3B)
7. Management of children and adolescents
7.1 Patients must receive advice on lifestyle modifica-
tions and on correcting non-cholesterol risk factors;
primordial prevention (counselling to inhibit the devel-
opment of risk factors) is particularly important. (2A)
7.2 To lower elevated plasma LDL-cholesterol in this
age group generally requires a fat-modified, heart-
healthy diet and a statin, with the possible addition of
ezetimibe or a bile acid sequestrant. (1A)
7.3 All patients should be treated with diet, with statins
considered at age eight to 10 years and ideally started
before age of 18 years; plasma LDL-cholesterol targets
in this age group need not be as intense as for adults. (2B)
7.4 Boys and girls should generally be treated at similar
ages, although with a particularly adverse family his-
tory of CHD and other major risk factors, boys with
heterozygous FH could be considered for earlier treat-
ment with statins. (2B)
7.5 Children, between the ages of eight and 10 years,
with proven FH on a suitable diet and LDL-cholesterol
>4.0mmol/l on two occasions should be started
on low-dose statin monotherapy, aiming for an LDL-
cholesterol <4.0mmol/l. (3C)
7.6 After the age of 10 years, children with proven FH
on a suitable diet and LDL-cholesterol >3.5mmol/l on
two occasions should be started on statin monotherapy,
aiming for an LDL-cholesterol <3.5mmol/l, with the
addition of ezetimibe or a bile acid sequestrant if
required. (3C)
7.7 The preferred statins for initiating therapy
are those that are licensed for clinical use in this
age group in specific countries; other statins may
be prescribed according to clinical indications,
higher doses of potent statins being required in homo-
zygotes. (1C)
7.8 Although statins can be safely used in children,
weight, growth, physical and sexual development,
and well-being should be monitored in this age
group. (1A)
7.9 Plasma levels of hepatic aminotransferases, creatine
kinase, glucose and creatinine should be measured
before starting drug therapy. All patients on statins
should have hepatic aminotransferases monitored; cre-
atine kinase should be measured and compared with
pre-treatment levels when musculoskeletal symptoms
are reported; glucose should be monitored if there are
risk factors for diabetes. (2A)
7.10 All adolescent girls should receive pre-pregnancy
counselling, with appropriate advice on contraception,
before starting a statin and this should be reinforced at
annual review. (3A)
7.11 Although carotid ultrasonography has been used
in clinical trials, its role in monitoring therapy in
patients with heterozygous FH has not been estab-
lished and it should therefore not be used for this
purpose. (3C)
7.12 Well controlled and lower complexity patients
should be followed up in primary care, whereas
higher complexity patients will need regular review by
a paediatrician. Opportunities should be created for
integrated care between GPs and paediatricians.
Family based and transitional care clinics should be
considered by adult and paediatric services. (3B)
7.13 Children with homozygous FH should be referred
on diagnosis to a specialist centre and drug and/or apher-
esis treatment commenced as soon as possible. (2A)
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7.14 In children with homozygous FH and rapidly pro-
gressive atherosclerosis, lomitapide and mipomersen,
although not yet tested in children, should be con-
sidered, employing special access or compassionate
use schemes, as adjunctive treatments to diet and con-
ventional drugs to further reduce plasma LDL-choles-
terol, particularly if apheresis is not available or
declined by the patient/family. (3C)
8. Lipoprotein apheresis and related treatments
8.1 Lipoprotein apheresis (LA) should be considered in
all patients with homozygous or compound heterozy-
gous FH (i.e. homozygous FH phenotype) and
carried out in a dedicated centre with the relevant
expertise. (1A)
8.2 LA should be considered in patients with heterozy-
gous FH with CHD who cannot achieve LDL-choles-
terol targets despite maximal drug therapy or because
they cannot tolerate statins. (2A)
8.3 LA should be considered in children with homozy-
gous FH by the age of five and no later than eight
years. (2A)
8.4 Diet and drug therapy to lower LDL-
cholesterol should be continued during treatment with
LA (2A).
8.5 The efficacy, tolerability and safety of LA must be
regularly reviewed. (3A)
8.6 The effect of LA on progression of atherosclerosis
should be monitored according to clinical indications in
FH patients with echocardiography (aortic valve and
root), carotid ultrasonography and exercise stress test-
ing. (3B)
8.7 Lomitapide should be considered as an adjunctive
to standard diet and drug therapy to further lower
plasma LDL-cholesterol in adults with homozygous
FH on LA. (1C)
8.8 Lomitapide should be considered, via a special
access scheme, as an adjunctive treatment to further
lower plasma LDL-cholesterol in children and adoles-
cents with homozygous FH on LA with rapidly pro-
gressive atherosclerosis. (3C)
8.9 Mipomersen should be considered as an adjunctive
to standard diet and drug therapy to further lower
plasma LDL-cholesterol in adults, children and adoles-
cents with homozygous FH on LA who cannot tolerate
lomitapide. (3C)
8.10 If available, orthotopic liver transplantation
should be considered for younger patients with
homozygous FH who have rapid progression of ath-
erosclerosis or aortic stenosis, cannot tolerate LA or
when plasma LDL-cholesterol cannot be adequately
lowered with LA, diet and drug treatment. (3B)
9. Organization and development of care
9.1 Care pathways for FH should be developed for
country-specific and local needs. (3A)
9.2 Specialist services should be multidisciplinary based
and integrated with primary care. (3B)
9.3 Specialist care of FH should ideally be supported by
cardiology, paediatric, genetic, imaging, transfusion
medicine, nursing, dietetic, psychology, pharmacy and
pathology laboratory services. (3A)
9.4 Cascade screening should ideally be centrally
co-ordinated by a dedicated centre. (1A)
9.5 Low complexity patients should be managed in
primary care, with the option of annual specialist
review. (3A)
9.6 Higher complexity patients should be managed
principally in specialist centres. (3A)
9.7 Medical, nursing and allied health staff managing
patients with FH should be accredited in cardiovascular
prevention. (3A)
9.8 Services should establish partnerships with aca-
demic and professional organizations to enhance teach-
ing, training and research. (3A)
9.9 A registry of patients and families should be estab-
lished for clinical, research and audit purposes. (3A)
9.10 A support group of patients and families should be
established as a major priority for enhancing public,
government and health care provider awareness, as
well as the total quality of care of FH. (3A)
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